Skip to main content

Share story

Science

QuTech demonstrates first cryogenic control chip for scalable diamond NV-center quantum computing

QuTech demonstrates first cryogenic control chip for scalable diamond NV-center quantum computing Image: Primary
QuTech researchers have demonstrated the first cryogenic control chip capable of directly managing both electron and nuclear spins in diamond-based qubits. The innovation integrates a cryo-CMOS system-on-chip with nitrogen-vacancy centers in diamond in a Fujitsu-funded project. The new controller brings electronics into the cold environment. It generates the precise high-frequency signals needed for spin manipulation while consuming minimal power and occupying minimal space. The integrated system reached quantum gate fidelities of 99.3 percent for electron spins and 99.8 percent for nuclear spins. Coherence times exceeded 50 milliseconds. Digital adaptation to each qubit resonance frequency removes the need for magnetic field tuning. This supports parallel control of multiple qubits. Masoud Babaie led the development with Fabio Sebastiano. The results will be presented at the IEEE International Solid-State Circuits Conference in February 2026. The Fujitsu and QuTech collaboration targets a full-stack blueprint for scalable quantum computing with diamond-spin qubit modules and cryogenic CMOS control electronics.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from QuTech and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.